H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Fri, 16 Oct 2026 08:14:01 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).

The analyst commented: "KOL event underscores ARIA as the factor that has capped uptake of approved anti-amyloid antibodies. On October 13, we hosted a key opinion leader (KOL) call with Dr. William Mantyh, a behavioral neurologist and Clinical Director of the Behavior & Memory Clinic at the University of Minnesota Medical School, who prescribes anti-amyloid therapies in daily practice. His explanation for why Leqembi (lecanemab) from Eisai and Kisunla (donanemab) from Eli Lilly & Co. have fallen short of the blockbuster trajectory that

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Mon, 12 Oct 2026 06:55:13 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).

The analyst commented: "Last week, ProMIS Neurosciences announced the appointment of Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino has deep expertise in neuroscience and particularly in Alzheimer’s disease (AD), spanning clinical development strategy, medical affairs, launch readiness, market development and commercialization. Her experience includes global leadership supporting the Leqembi (lecanemab) franchise, preparation for next-generation AD therapies, and the build-out of large global medical organizations across major markets worldwide. She also held senior global leadership roles across multiple

Form 4 ProMIS Neurosciences For: Oct 05 Filed by: Rubino Ivana

Tue, 06 Oct 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20261006/27156282.html

Form 3 ProMIS Neurosciences For: Oct 05 Filed by: Rubino Ivana

Tue, 06 Oct 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20261006/27156268.html

ProMIS Neurosciences names former Biogen executive as chief commercial officer

Tue, 06 Oct 2026 07:05:15 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) has appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026, according to a company statement.

Dr. Rubino joins from Biogen, where she most recently served as Vice President and Global Head of Alzheimer's Disease and Multiple Sclerosis Medical. In that role, she led global medical strategy and launch readiness, served as alliance medical strategy leader with Eisai, and supported the global development of LEQEMBI across 52 market approvals. Prior to Biogen, she held medical affairs, commercial and regulatory roles at F. Hoffmann-La Roche AG in Basel, Switzerland.

In her new role, Dr. Rubino will

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

Tue, 06 Oct 2026 07:05:00 -0400

Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy

Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027

CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer’s disease, today announced the appointment of Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026.

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

Tue, 06 Oct 2026 07:05:00 -0400

Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy

Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Tue, 01 Sep 2026 08:00:00 -0400

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

Conference details below:

September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Tue, 01 Sep 2026 08:00:00 -0400

Conference details below:

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925875.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925875.html

ProMIS Neurosciences (PMN) PT Raised to $100 at Guggenheim

Fri, 14 Aug 2026 08:37:44 -0400

Guggenheim analyst Eddie Hickman raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $100.00 (from $69.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Thu, 13 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26921810.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Thu, 13 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26921810.html

Form 8-K ProMIS Neurosciences For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920951.html

Form 8-K ProMIS Neurosciences For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920951.html

Form 10-Q ProMIS Neurosciences For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920897.html

Form 10-Q ProMIS Neurosciences For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920897.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26920800.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26920800.html

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Thu, 13 Aug 2026 16:00:00 -0400

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.
Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.
The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond the Company’s anticipated 12-month topline PRECISE-AD

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Thu, 13 Aug 2026 16:00:00 -0400

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.
Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.
The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond the Company’s anticipated 12-month topline PRECISE-AD

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

Fri, 07 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260807/26890787.html

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

Fri, 07 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260807/26890787.html

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Mon, 03 Aug 2026 16:00:00 -0400

Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.

The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.

StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Form 4 ProMIS Neurosciences For: Oct 05 Filed by: Rubino Ivana

Form 3 ProMIS Neurosciences For: Oct 05 Filed by: Rubino Ivana

ProMIS Neurosciences names former Biogen executive as chief commercial officer

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

ProMIS Neurosciences (PMN) PT Raised to $100 at Guggenheim

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Form 8-K ProMIS Neurosciences For: Aug 13

Form 8-K ProMIS Neurosciences For: Aug 13

Form 10-Q ProMIS Neurosciences For: Jun 30

Form 10-Q ProMIS Neurosciences For: Jun 30

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026